scientific and microscope

Our clinical studies

We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.

 

Clinical studies

This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.

 

Total studies

0

Current studies

0

Oncology

0

Dermatology

0

Rare diseases

0

Others

0
Show more filters
Title Therapeutic area Phase Status Start date (Planned) End date

Post-operative care by chlorhexidine mouthwash after periodontal surgery. Randomised, parallel groups; blind study, DC071BB versus placebo, in patients presenting with periodontal surgery with suture

dental Phase IV Completed November 2005 June 2006

Long term management of atopic dermatitis with the emollient V0034CR. A randomised, placebo-controlled, parallel groups, double-blind study in infants and children

Dermatology Phase III Completed November 2005 November 2006

The effect of Minalcipran 100mg BID on sensitivity to stimulus-evoked pain in patients with Fibromyalgia : a FMRI neuroimaging study

Central Nervous System Phase II Completed October 2005 April 2007

Phase II Study of Navelbine oral and Arimidex as neo-adjuvant treatment in post-menopausal women with locally advanced breast carcinoma

Oncology Phase II Completed July 2005 February 2009

Randomised phase II study of the combination of oral vinorelbine with capecitabine versus a sequential regimen of oral vinorelbine and capecitabine versus the combination of docetaxel and capecitabine...

Oncology Phase II Completed June 2005 December 2010

Oral Vinorelbine and Cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral Vinorelbine and Cispalatine plus best supportive care or best supportive care alone in stage III Non Small Cell Lung Cancer (NSCLC): randomized Phase III study

Oncology Phase III Early termination May 2005 May 2012

Efficacy and safety of 0,1%, 0,5% and 1% TAZAROTENE nail lacquer formulation versus vehicle in nail psoriasis. International, multicenter, double-blind, randomized study of four parallel groups

Dermatology Phase II Completed April 28, 2005 May 08, 2006

Cross over comparison of Testosterone serum levels in Hypogonadal men treated with L0074 Testosterone Patch 60 cm2 (2 patches/48H) and oral Testosterone Undecaoate -PANTESTONE® 40mg- (2 caps, bid)

Hormonal Phase III Completed March 2005 September 2005

Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer

Oncology Phase II Completed November 2004 November 2007

A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines

Oncology Phase II Completed September 2004 June 2007

Ensayo clínico en fase I-II de vinorelbina oral (Navelbine) en combinación con capecitabina en tratamiento de primera línea en pacientes con cáncer de mama avanzado

Oncology Phase I Completed September 2004 October 2009

Efficacy of the topic RV3131A-HC3221 in the prevention of polymorphic light eruption

Dermatology Phase II Completed September 2004 February 2006

Phase II study of oral vinorelbine in combination with capecitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes

Oncology Phase II Completed September 2004 December 2007

Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer

Oncology Phase II Completed March 2004 May 2019

Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic non...

Oncology Phase III Completed February 2004 January 2006

Get access to Partner's pivotal studies supporting our authorized drugs in Europe

Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below:

 

Melanoma

SPONSOR: PFIZER

Breast cancer 

SPONSOR: PUMA BIOTECHNOLOGY

Colorectal cancer

SPONSOR: PFIZER

Post-transplantation lymphoproliferative disease EBV+

SPONSOR: ATARA